Endoglin polypeptides and uses thereof
AssigneeAcceleron Pharma Inc.
InventorAsya Grinberg
Life of this patent
Estimating the term…
Abstract
In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a truncated, ligand-binding portion of the extracellular domain of endoglin (ENG) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders.
Claims24
An endoglin polypeptide comprising an amino acid sequence at least 95% identical to amino acids 42-333 of SEQ ID NO:
- 1, wherein the endoglin polypeptide does not include a sequence consisting of amino acids 379-430 of SEQ ID NO:
- 1.
(canceled)
An endoglin polypeptide comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions to a complement of a nucleotide sequence selected from a group consisting of:
- a. nucleotides 537-1412 of SEQ ID NO:
- 2 [encoding hENG(42-333)],
- b. nucleotides 121-1035 of SEQ ID NO:
- 30 [encoding hENG(42-346)],
- c. nucleotides 121-1074 of SEQ ID NO:
- 26 [encoding hENG(42-359)],
- d. nucleotides 121-1131 of SEQ ID NO:
- 24 [encoding hENG(42-378)],
- e. nucleotides 73-1035 of SEQ ID NO:
- 30 [encoding hENG(26-346)],
- f. nucleotides 73-1074 of SEQ ID NO:
- 26 [encoding hENG(26-359)], and
- g. nucleotides 73-1131 of SEQ ID NO:
- 24 [encoding hENG(26-378)], wherein the endoglin polypeptide does not include a sequence consisting of amino acids 379-430 of SEQ ID NO:
- 1.
18-28. (canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.